ArticleBreast cancer (Tokyo, Japan)2018

Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer: JBCRG-18 cape study.

Masaya Hattori et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.